Dabigatran and rivaroxaban have different risk factors for bleeding in atrial fibrillation patients

被引：0
|
作者：
Nishino, M. [1 ]
Okamoto, N. [1 ]
Tanaka, A. [1 ]
Mori, N. [1 ]
Yoshimura, T. [1 ]
Makino, N. [1 ]
Egami, Y. [1 ]
Shutta, R. [1 ]
Tanouchi, J. [1 ]
机构：
[1] Osaka Rosai Hosp, Sakai, Osaka 5918025, Japan
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6201
引用
收藏
页码：1080 / 1080
页数：1
相关论文
共 50 条
  • [1] Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban
    Nishino, Masami
    Okamoto, Naotaka
    Tanaka, Akihiro
    Mod, Naoki
    Hara, Masahiko
    Yano, Masamichi
    Makino, Nobuhiko
    Egami, Yasuyuki
    Shutta, Ryu
    Tanouchi, Jun
    [J]. JOURNAL OF CARDIOLOGY, 2016, 68 (1-2) : 156 - 160
  • [2] Risk of Bleeding With Dabigatran in Atrial Fibrillation
    Hernandez, Inmaculada
    Baik, Seo Hyon
    Pinera, Antonio
    Zhang, Yuting
    [J]. JAMA INTERNAL MEDICINE, 2015, 175 (01) : 18 - 24
  • [3] Bleeding in patientswith atrial fibrillation treated with dabigatran, rivaroxaban or warfarin
    Kawada, Tomoyuki
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 38 : E20 - E20
  • [4] Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation
    Adeboyeje, Gboyega
    Sylwestrzak, Gosia
    Barron, John J.
    White, Jeff
    Rosenberg, Alan
    Abarca, Jacob
    Crawford, Geoffrey
    Redberg, Rita
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (09): : 968 - 978
  • [5] A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk
    Liu, Penghui
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [6] Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation
    Tamayo, Sally G.
    Simeone, Jason C.
    Nordstrom, Beth L.
    Patel, Manesh R.
    Yuan, Zhong
    Sicignano, Nicholas M.
    Peacock, W. Frank
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (10) : 1144 - 1146
  • [7] Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran
    Holt, Anders
    Strange, Jarl E.
    Rasmussen, Peter Vibe
    Blanche, Paul
    Nouhravesh, Nina
    Jensen, Mads Hashiba
    Schjerning, Anne-Marie
    Schou, Morten
    Torp-Pedersen, Christian
    Gislason, Gunnar H.
    Hansen, Morten Lock
    McGettigan, Patricia
    Lamberts, Morten
    [J]. AMERICAN JOURNAL OF MEDICINE, 2022, 135 (05): : 595 - +
  • [8] Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
    Kirchhof, Paulus
    Haas, Sylvia
    Amarenco, Pierre
    Hess, Susanne
    Lambelet, Marc
    van Eickels, Martin
    Turpie, Alexander G. G.
    Camm, A. John
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (05):
  • [9] Risk factors and prevention of dabigatran-related gastrointestinal bleeding in patients with atrial fibrillation
    Nantsupawat, Teerapat
    Soontrapa, Suthipong
    Nantsupawat, Nopakoon
    Sotello, David
    Klomjit, Saranapoom
    Adabag, Selcuk
    Perez-Verdia, Alejandro
    [J]. JOURNAL OF ARRHYTHMIA, 2018, 34 (01) : 30 - 35
  • [10] The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation
    Klil-Drori, Adi
    Azoulay, Laurent
    [J]. JAMA INTERNAL MEDICINE, 2015, 175 (07) : 1243 - 1244
12345